[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diffuse-glioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diffuse-glioma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,78,100,133,155,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100629060","vorasidenib-guided-by-agx-pet-in-recurrentlow-grade-glioma-100629060",false,"NCT07469735","Vorasidenib Guided by AGX PET in Recurrent\u002FLow-grade Glioma","18F-AGX PET for Evaluation of Vorasidenib Response and Tumor Metabolic Changes in Low-grade IDH-Mutant Glioma","VANGUARD","Inclusion Criteria:\n\n1. Histologically or molecularly confirmed WHO 2021 grade 2 or 3 IDH1\u002F2-mutant diffuse glioma with recurrent or residual disease\n2. At least one measurable non-enhancing lesion (≥1 cm × ≥1 cm) on postoperative T2\u002FFLAIR MRI\n3. Eligible for Vorasidenib treatment\n4. Age ≥18 years\n5. Karnofsky Performance Status (KPS) score ≥80\n6. Adequate hematologic function\n7. Adequate renal function\n8. Adequate hepatic function\n9. Ability to provide written informed consent\n\nExclusion Criteria:\n\n1. Prior treatment with radiotherapy, chemotherapy, or IDH inhibitors\n2. Known contraindications to Vorasidenib\n3. Contraindications to PET\u002FCT imaging\n4. Uncontrolled hyperglycemia\n5. Pregnancy or breastfeeding\n6. Inability to undergo repeated intravenous injections\n7. Known hypersensitivity to imaging agents or study-related medications\n8. Use of strong CYP1A2 inhibitors or CYP2C19 or CYP3A substrates with narrow therapeutic index\n9. Any serious comorbid condition that may interfere with study participation or safety","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this prospective, single-arm, open-label clinical trial is to evaluate whether 18F-AGX PET imaging can be used to assess early treatment response and metabolic changes in adult patients with recurrent or residual WHO 2021 grade 2-3 IDH-mutant diffuse glioma receiving Vorasidenib therapy.\n\nIDH-mutant diffuse gliomas often show slow tumor growth, making early treatment response difficult to evaluate using conventional structural imaging such as magnetic resonance imaging (MRI). Clinical endpoints such as progression-free survival (PFS) and overall survival (OS) typically require long follow-up periods to detect treatment effects. Therefore, the development of sensitive and noninvasive imaging methods for early evaluation of therapeutic response is needed.\n\nThis study aims to determine whether metabolic changes detected by 18F-AGX PET during Vorasidenib treatment are associated with tumor structural changes and clinical outcomes.\n\nThe main questions it aims to answer are:\n\n* Whether early changes in tumor metabolic activity measured by 18F-AGX PET, including percentage change in maximum tumor-to-background ratio (TBRmax), are associated with changes in tumor growth rate (TGR) measured by MRI during treatment.\n* Whether early metabolic response detected by 18F-AGX PET imaging after initiation of Vorasidenib treatment can predict subsequent disease progression or tumor growth dynamics.\n\nParticipants enrolled in this study will receive oral Vorasidenib once daily for 12 treatment cycles (28 days per cycle), with dosing based on body weight.\n\nParticipants will:\n\n* Undergo baseline MRI and 18F-AGX PET imaging following surgery for recurrent or residual disease.\n* Receive oral Vorasidenib continuously for 12 cycles.\n* Undergo MRI scans at baseline and during treatment cycles 1, 2, 3, 6, 9, and 12 to assess structural tumor changes.\n* Undergo 18F-AGX PET\u002FCT scans at baseline and during treatment cycles 1, 2, 3, 6, and 12 to assess metabolic tumor activity.\n* Provide serial blood samples for laboratory safety monitoring, including hematologic and biochemical testing.\n* Undergo magnetic resonance spectroscopy (MRS) to quantify intratumoral 2-hydroxyglutarate (2-HG) levels as an indicator of IDH mutation-associated metabolic activity.\n\nParticipants will be followed for imaging-based disease progression using RANO criteria and for treatment-related adverse events during the study period.\n\nThis study will evaluate the feasibility of using 18F-AGX PET imaging as a noninvasive imaging biomarker for early response assessment in IDH-mutant diffuse glioma patients receiving targeted IDH inhibition therapy with Vorasidenib.",[27,28,29],"Glioma","Diffuse Glioma","Recurrent Gliomas",[31,32,33,34],"IDH Mutation","Vorasidenib","Positron Emission Tomography","Treatment Response","NOT_YET_RECRUITING","2026-03-09",{"date":38,"type":39},"2026-03-13","ACTUAL",{"date":41,"type":21},"2026-04-01",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"Huashan Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100481748","early-phase-1-18f-fluciclovine-pet-mri-in-high-grade-glioma-100481748","NCT05553041","18F-Fluciclovine PET-MRI in High-grade Glioma","Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)","Inclusion Criteria\n\n* 1\\. Histopathology-proven HGG (WHO grade III-IV) or DMG (WHO grade IV) or, in the case of DMG of the pons, imaging that is characteristic of Diffuse intrinsic pontine gliomas (DIPG) (diffusely infiltrating \\>=2\u002F3 of the pons).\n* 2\\. Measurable disease, measuring at least 1x1 cm.\n* 3\\. Life expectancy of greater than 8 weeks.\n* 4\\. Age \\> 1 years but \\< 21 years of age at enrollment.\n\nFor those without planned surgery:\n\n* 1\\. Participants with clinical and\u002For radiographic suspicion of True progression (TP) or Pseudoprogression (PsP) during radiation but yet to have the initial post-radiation MRI scan.\n\nor\n\n* 2\\. Participants with suspicion for TP or PsP on first post-radiation MRI\n\nFor those with planned surgery:\n\n* 1\\. Clinical or radiographic suspicion of tumor progression with plan to undergo surgery or biopsy.\n\nExclusion Criteria:\n\n* 1\\. Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.\n* 2\\. Pregnant or breastfeeding participants.\n* 3\\. Participant who would require sedation or anesthesia for imaging beyond standard of care (SOC).\n* 4\\. Participants who weigh less than 8 kg.\n* 5\\. Participants who cannot avoid contact with a pregnant woman or infant for at least 12 hours following injection.\n* 6\\. Participants with a history of abnormal kidney function or creatinine \\>= CTCAE v5.0 grade 2 at time of study registration.\n\n  7\\. Participants with primary tumors of the spinal cord.","1 Year","21 Years",{"count":58,"type":21},30,[60],"EARLY_PHASE1","The purpose of this study is to see if 18F-fluciclovine (Axumin®) PET imaging is useful and safe in the management of children with High Grade Gliomas. Investigators seek to determine if this imaging will help doctors tell the difference between tumor growth (progression) and other tumor changes that can occur after treatment.",[27,63,64,65,28],"High Grade Glioma","Glioma, Malignant","Glioma Intracranial",[27,63,64,65,28,67],"18F fluciclovine","RECRUITING","2025-12-03",{"date":71,"type":39},"2025-12-04",{"date":73,"type":39},"2024-08-07",{"date":75,"type":21},"2027-12",{"name":77,"class":46},"Children's Hospital of Philadelphia",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":47},"100494359","early-phase-1-intratumoral-extracellular-metabolic-impact-of-dfmo-and-amxt-1501-in-patients-with-diffuse-or-high-grade-glioma-100494359","NCT05717153","Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma","Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Clinical and radiographic evidence suggesting a diagnosis of a diffuse high grade glioma (HGG), or a prior diagnosis of a diffuse glioma\n* Planned subtotal resection or biopsy due to tumor location, size, or other clinical indication deemed appropriate by the surgeon\n* Provide written informed consent for the current study and the Neuro-Oncology biorepository for archiving of cerebrospinal fluid (CSF) and blood samples collected on this protocol. Willing to remain in the hospital at Mayo Clinic (Rochester, MN) for three days added to their standard post-operative stay to undergo longitudinal microdialysis\n* Absolute neutrophil count (ANC) \\>= 1.5 x 10\\^9\u002FL without transfusion within 7 days preceding the lab assessment (obtained =\\\u003C 14 days prior to registration)\n* Platelet \\>= 100 x 10\\^9\u002FL, without transfusion within 7 days preceding the lab assessment (obtained =\\\u003C 14 days prior to registration)\n* Hemoglobin \\>= 9 g\u002FdL, without transfusion support within 7 days preceding the lab assessment (obtained =\\\u003C 14 days prior to registration)\n* Activated partial thromboplastin time or partial thromboplastin time (aPTT or PTT) =\\\u003C 1.5 x upper limit of normal (ULN) (obtained =\\\u003C 14 days prior to registration)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 2.5 x ULN (obtained =\\\u003C 14 days prior to registration)\n* Total serum bilirubin =\\\u003C 1.5 x ULN (obtained =\\\u003C 14 days prior to registration)\n* The patient is clinically euthyroid \\[Thyroid Stimulating Hormone (TSH)\\]\n* Serum creatinine =\\\u003C 1.5 x ULN or creatinine clearance \\>= 60 mL\u002Fmin\u002F1.73 m\\^2 for patients with serum creatinine levels above 1.5 x ULN (obtained =\\\u003C 14 days prior to registration)\n* Negative serum or urine pregnancy test is required for female subjects of childbearing age \\\u003C 14 days prior to registration\n\nExclusion Criteria:\n\n* Inappropriate surgical candidates due to current or past medical history or uncontrolled concurrent illness which limits safety of or compliance to study proceedings\n* Vulnerable populations: pregnant or nursing women, prisoners, mentally handicapped\n* Unable to swallow tablets or who are at risk for impaired absorption of oral medication. NOTE: This includes but not limited to, refractory vomiting, gastric resection\u002Fbypass, and duodenal\u002Fjejunal resection\n* Known hypersensitivity or allergy to DFMO or AMXT 1501\n* Contraindication to MRI or administration of gadolinium",{"count":86,"type":21},18,[60],"This early phase I trial studies brain tumor (glioma) metabolism in response to eflornithine (DFMO) and polyamine transport inhibitor AMXT-1501 dicaprate (AMXT 1501) in patients with diffused or high grade glioma. Brain tumors use and produce certain molecules to survive and grow. DFMO is an irreversible inhibitor of ornithine decarboxylase, the enzyme catalyzing polyamine synthesis. AMXT 1501 is a polyamine transport inhibitor which prevents uptake of polyamines from the extracellular environment. This trial is being done to analyze how DFMO and AMXT 1501 affect brain tumor metabolism based on the molecules in the tumor's fluid.",[28,90],"Malignant Glioma","2025-10-31",{"date":93,"type":39},"2025-11-04",{"date":95,"type":39},"2023-10-01",{"date":97,"type":21},"2027-09-15",{"name":99,"class":46},"Mayo Clinic",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":47},"100579989","proton-versus-photon-radiotherapy-in-adults-with-primary-brain-tumors-100579989","NCT06831461","Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors","Proton Versus Photon Radiotherapy In Adults With Primary Brain Tumors Evaluating Functional Survival: A Phase 3 Randomized Controlled Trial (PRIDE)","PRIDE","Inclusion Criteria:\n\n* Primary brain tumors\n* Age at irradiation: 18 to 70 years\n* Karnofsky Performance Status ≥ 60\n* Diagnosis (histopathological\u002F radiological) of primary brain tumor with an expected survival of \\>5 years (e.g., grade 2-3 diffuse glioma, low-grade glial\u002F glioneuronal tumors, ependymoma, meningioma, pituitary tumors, schwannoma, craniopharyngioma, etc.)\n* Planned for focal cranial radiotherapy\n* Informed consent taken\n\nExclusion Criteria:\n\n* Re-irradiation\n* Palliative radiotherapy\n* Multifocal or multicentric disease\n* Planned for whole brain irradiation or craniospinal irradiation\n* Planned for hypo-fractionated or stereotactic radiotherapy","70 Years",{"count":110,"type":21},156,[24],"This study will be done in adults with brain tumors having good prognosis requiring treatment with radiotherapy. The current practice for brain radiotherapy involves treatment using X rays (photon radiotherapy). Proton beam therapy is a more advanced form of delivering radiation, which allows the reduction of the dose of radiation to the parts of the brain surrounding the tumor. After treatment with photon radiotherapy, certain late effects of radiation, like memory decline, hormonal deficits, hearing loss, and worsening of neurological function, can occur in some patients. From the evaluation of dose profiling, proton beam therapy has the potential to reduce the possibility of side effects by reducing the dose to critical organs. However, there is no clinical data to demonstrate whether the theoretical dose reduction translates to a clinically meaningful benefit. In the proposed study, 156 patients will be randomly allocated to either proton or photon radiotherapy in 1: 1 ratio. The primary objective of the study is to explore whether proton therapy improves functional survival, which is life expectancy without recurrence, death, or complications from radiotherapy.",[114,28,115,116,117],"Primary Brain Tumors","Meningioma","Pituitary Adenoma","Low Grade CNS Tumors",[119,120,121,122,123],"Proton Beam Therapy","Photon Radiotherapy","Brain Tumors","Neurocognition","Survival","2025-09-15",{"date":126,"type":39},"2025-09-16",{"date":128,"type":39},"2025-07-01",{"date":130,"type":21},"2032-12-31",{"name":132,"class":46},"Tata Memorial Centre",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":4},"100553930","phase-2-glioma-adaptive-radiotherapy-with-development-of-an-artificial-intelligence-workflow-100553930","NCT06492486","Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow","GLADIATOR","Inclusion Criteria:\n\n* Histological diagnosis of diffuse glioma. Patients with IDH-negative GBM (stratum A) and IDH-mutant glioma (astrocytoma or oligodendroglioma) need radiotherapy (stratum B).\n\nAge: 18-70 years. Karnofsky Performance Scale (KPS) ≥60\n\nExclusion Criteria:\n\n* Multifocal or multicentric disease Not eligible for radical intent radiation. IDH status is unknown or uninterpretable (IHC or gene sequencing). Use of prior radiotherapy to the head-neck region or brain or chemotherapy. Contraindication\u002Funable to undergo MRI or PET scan during radiation.",{"count":141,"type":21},60,[143],"PHASE2","Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. The common types of diffuse gliomas include glioblastoma, astrocytoma, and oligodendroglioma. The standard treatment for diffuse gliomas includes surgery followed by radiation and chemotherapy. As per standard institutional practice, a uniform dose of radiation is delivered to the disease area and MRI is done before and after the treatment. In this study, MRI and PET scan will be done before starting the treatment and standard dose of radiation will be delivered. The interval imaging will be done twice during the course of treatment with MRI and PET, followed by dose modifications. The CT, MRI, and PET will be combined. Based on PET imaging, specific dose will be altered and delivered to specific areas. Dose modification will be done with the help of artificial intelligence. Participant's assessment will be done at regular intervals.\n\nModifications in radiation plans are done based on the changes in disease seen in scans is likely to improve the accuracy of RT treatments. Dose modifications based on imaging to resistant areas will help achieve better tumor control, reduce treatment-related toxicities, precise delivery of the RT and adjusting doses to the organs at risk (OAR) and changes in disease leading to better treatment compliance. Creating an artificial intelligence framework in radiation oncology promises to improve quality of workflow, treatment planning and RT delivery.\n\nThe aim of the study is to develop an artificial intelligence workflow for treatment of glioma with adaptive radiotherapy. This study will be conducted in Tata Memorial Centre on a population of 60 patients for a duration of 2 years. The total study duration is 4 years.",[28,146,147,148],"Glioblastoma","Adaptive Radiotherapy","Artificial Intelligence",{"date":126,"type":39},{"date":151,"type":21},"2025-11-30",{"date":153,"type":21},"2028-07-30",{"name":132,"class":46},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":47},"100517354","phase-2-a-study-of-chlorophyllin-for-the-management-of-brain-radio-necrosis-in-patients-with-diffuse-glioma-100517354","NCT06016452","A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma","A Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma","CHROME","Inclusion Criteria:\n\n* Histological diagnosis of diffuse glioma.\n* Radionecrosis on imaging with new neurological symptoms\u002F worsening of prior deficits (Stratum A) or\n* without new symptoms (Stratum B).\n* Karnofsky Performance Scale (KPS) ≥ 50.\n\nExclusion Criteria:\n\n* No tissue diagnosis.\n* KPS\\\u003C 50.\n* Disease progression\n* Contraindications to corticosteroids.\n* Altered mental status with deficits in understanding or inability to consent to the study.\n* Brainstem glioma\n* Indeterminate for radionecrosis vs disease progression\n* Prior treatment with bevacizumab (either for disease progression or radionecrosis)",{"count":164,"type":21},118,[143],"Diffuse gliomas are common tumors involving the brain. They are usually treated by surgery followed by radiation and chemotherapy. Radiotherapy is used for the treatment of brain tumors which causes damage to the tumor cells. However, radiotherapy can also affect the surrounding healthy cells in the brain, causing inflammation and swelling in the region, which is known as radio necrosis (RN). This is considered a late side effect of radiation and is seen in 10-25% of patients treated with radiation for brain tumors. Sometimes, radionecrosis can be detected on routine imaging during follow-up without new symptoms (asymptomaticRN).\n\nAt the same time, in some patients, it can give rise to new symptoms like headaches, weakness, seizures,etc (symptomatic RN). The standard treatment of RN includes steroid medicines called dexamethasone, which is helpful in a proportion of patients.\n\nThis is a prospective phase 2 study. This study is being conducted to investigate the ability of the drug Chlorophyllin in the treatment of radionecrosis.\n\nChlorophyllin is a water-soluble compound obtained from the green plant pigment called chlorophyll. It has been shown to have anti-cancer, anti-bacterial, anti-viral, anti-inflammatory, and antioxidant properties. It is also used as an oral formulation and is an over-the-counter drug in various countries, and also as a food colouring agent.\n\nThis is the first time chlorophyllin will be used in the setting of brain radionecrosis. Our primary aim of the study is to assess whether CHL will improve the clinical-radiological response rates. This study will be conducted on a population of 118 patients for a duration of 3 months. The total study duration is 2 years.\n\nThe study is funded by Bhabha Atomic Research Centre (BARC).",[28,168,63,169],"Radionecrosis of Brain","Glioblastoma Multiforme","2025-04-08",{"date":172,"type":39},"2025-04-11",{"date":174,"type":39},"2023-11-13",{"date":176,"type":21},"2025-11",{"name":132,"class":46},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":17,"minAge":185,"maxAge":56,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":4},"100523249","re-irradiation-of-diffuse-midline-glioma-patients-100523249","NCT06093165","RE-irradiation of Diffuse MIdline Glioma paTients","REMIT","Inclusion Criteria:\n\n* Diffuse midline glioma diagnosis: verified radiologically or histologically Biopsy is not mandatory for REMIT\n* Age ≥ 12 months to ≤21 years.\n* Min. 180 days\u002F6 months have elapsed from the first day of the 1st RT course\n* 1st course of radiotherapy\n* Full recovery from all acute and subacute toxicities of 1st RT course\n* Clinical progression of symptoms and\u002For radiographic progression\n* Karnofsky performance status scale or Lansky Play Scale \\> 50% The performance status should not take the neurological deficits per se into account.\n\nNB: Children and adults with a worsening performance status due to glioma-related motor deficit can be included.\n\n* Life expectancy \\> 12 weeks after start of reRT\n* Signed informed consent by patient and\u002For parents or legal guardian\n\nExclusion Criteria:\n\n* Presence of leptomeningeal spread or multifocal disease on MRI at progression\n* Other co-morbidity that according to the treating physician would impair participation in the study\n* \\>1 course of radiotherapy\n* Neurofibromatosis type 1\n* Inability to complete the medical follow-up (geographic, social, or mental reasons)","12 Months",{"count":187,"type":21},59,[24],"The REMIT (RE-irradiation of diffuse MIdline glioma paTients) study evaluates safety and the palliative efficacy of re-irradiation of patients with diffuse midline glioma (DMG). The study will introduce a standard re-irradiation treatment schedule for DMG patients who have progressed following primary treatment.",[191,192,28,193,194,195],"Diffuse Midline Glioma, H3 K27M-Mutant","Diffuse Intrinsic Pontine Glioma","Pontine Tumors","Thalamic Tumor","Brain Tumor, Pediatric","2023-10-16",{"date":198,"type":39},"2023-10-23",{"date":200,"type":21},"2023-10",{"date":202,"type":21},"2029-11",{"name":204,"class":46},"Rigshospitalet, Denmark"]